IL33 Antibody - #DF8319

(6)   (10)  
Product: IL33 Antibody
Catalog: DF8319
Description: Rabbit polyclonal antibody to IL33
Application: WB IHC IF/ICC
Reactivity: Human, Mouse, Rat
Mol.Wt.: 31 kDa; 31kD(Calculated).
Uniprot: O95760
RRID: AB_2841596

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MS Report
HPLC Report
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
WB 1:1000-3000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Clonality:
Polyclonal
Specificity:
IL33 Antibody detects endogenous levels of total IL33.
RRID:
AB_2841596
Cite Format: Affinity Biosciences Cat# DF8319, RRID:AB_2841596.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

C9orf26; CHROMOSOME 9 OPEN READING FRAME 26; DKFZp586H0523; DVS27; DVS27 related protein; IL 1F11; IL 33; IL-1F11; IL-33; IL1F11; IL33; IL33_HUMAN; Interleukin 1 family member 11; Interleukin 33; INTERLEUKIN 33 NFHEV; Interleukin 33 precursor; Interleukin-1 family member 11; Interleukin-33 (109-270); Interleukin33; NF HEV; NF-HEV; NFEHEV; NFHEV; Nuclear factor for high endothelial venules; Nuclear factor from high endothelial venules; OTTHUMP00000021041; RP11 575C20.2;

Immunogens

Immunogen:
Uniprot:

O95760(IL33_HUMAN) >>Visit HPA database.

Gene(ID):
IL33(90865)
Expression:
O95760 IL33_HUMAN:

Expressed at high level in high endothelial venules found in tonsils, Peyer patches and mesenteric lymph nodes. Almost undetectable in placenta.

Sequence:
MKPKMKYSTNKISTAKWKNTASKALCFKLGKSQQKAKEVCPMYFMKLRSGLMIKKEACYFRRETTKRPSLKTGRKHKRHLVLAACQQQSTVECFAFGISGVQKYTRALHDSSITGISPITEYLASLSTYNDQSITFALEDESYEIYVEDLKKDEKKDKVLLSYYESQHPSNESGDGVDGKMLMVTLSPTKDFWLHANNKEHSVELHKCEKPLPDQAFFVLHNMHSNCVSFECKTDPGVFIGVKDNHLALIKVDSSENLCTENILFKLSET

PTMs - O95760 As Substrate

Site PTM Type Enzyme
K16 Acetylation

Research Backgrounds

Function:

Cytokine that binds to and signals through the IL1RL1/ST2 receptor which in turn activates NF-kappa-B and MAPK signaling pathways in target cells. Involved in the maturation of Th2 cells inducing the secretion of T-helper type 2-associated cytokines. Also involved in activation of mast cells, basophils, eosinophils and natural killer cells. Acts as a chemoattractant for Th2 cells, and may function as an 'alarmin', that amplifies immune responses during tissue injury.

In quiescent endothelia the uncleaved form is constitutively and abundantly expressed, and acts as a chromatin-associated nuclear factor with transcriptional repressor properties, it may sequester nuclear NF-kappaB/RELA, lowering expression of its targets. This form is rapidely lost upon angiogenic or proinflammatory activation.

PTMs:

The full-length protein can be released from cells and is able to signal via the IL1RL1/ST2 receptor. However, proteolytic processing by CSTG/cathepsin G and ELANE/neutrophil elastase produces C-terminal peptides that are more active than the unprocessed full length protein. May also be proteolytically processed by calpains. Proteolytic cleavage mediated by apoptotic caspases including CASP3 and CASP7 results in IL33 inactivation. In vitro proteolytic cleavage by CASP1 was reported but could not be confirmed in vivo suggesting that IL33 is probably not a direct substrate for that caspase.

Subcellular Location:

Nucleus. Chromosome. Cytoplasmic vesicle>Secretory vesicle. Secreted.
Note: Associates with heterochromatin and mitotic chromosomes (PubMed:17185418).

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Expressed at high level in high endothelial venules found in tonsils, Peyer patches and mesenteric lymph nodes. Almost undetectable in placenta.

Subunit Structure:

Forms a 1:1:1 heterotrimeric complex with its primary high-affinity receptor IL1RL1 and the coreceptor IL1RAP.

(Microbial infection) Interacts (in reduced form) with H.polygyrus ARI.

Family&Domains:

The homeodomain-like HTH domain mediates nuclear localization and heterochromatin association.

Belongs to the IL-1 family. Highly divergent.

Research Fields

· Cellular Processes > Cell growth and death > Necroptosis.   (View pathway)

· Human Diseases > Infectious diseases: Viral > Influenza A.

· Organismal Systems > Immune system > Cytosolic DNA-sensing pathway.   (View pathway)

References

1). Honokiol suppresses the aberrant interactions between renal resident macrophages and tubular epithelial cells in lupus nephritis through the NLRP3/IL-33/ST2 axis. Cell Death & Disease (PubMed: 36859530) [IF=9.0]

Application: WB    Species: Mouse    Sample:

Fig. 6: NLRP3 regulates IL-33 expression in renal resident macrophages.
2). Oesophageal squamous cell carcinoma–associated IL‐33 rewires macrophage polarization towards M2 via activating ornithine decarboxylase. CELL PROLIFERATION (PubMed: 33305406) [IF=8.5]

Application: IHC    Species: mouse    Sample: tumour

FIGURE 6|The pro-tumour effect of IL-33 in vivo. A, Xenograft tumour growth curve. B, Tumour weight on day 21 after the first administration in each group. C, The body weight change in mice. Results are expressed as mean ± SEM (n = 5; **P < .01, ***P < .001). D, Kaplan-Meier survival curves of mice received different treatments, n = 10 mice per group. E, H&E staining of tumour tissues (scale bar = 200 μm). ***P < .001. Bars indicate mean and SEM of triplicate experiments and show a representative experiment of at least 3 independent experiments performed for each panel

Application: IF/ICC    Species: human    Sample: M2 macrophages

FIGURE 4|IL-33 promotes M2 macrophage polarization via ornithine decarboxylase (ODC) activation. A, IL-10, TGF-β and IL12p35 protein levels were determined by Western blot in IL-33–induced M2 macrophage with or without knocking down ODC. B, Immunofluorescence staining for IL-33–induced M2 macrophages with or without knocking down ODC. The red signal represents the staining of ODC, and the green signal represents the staining of ARG1 (scale bar = 20 μm).

Application: WB    Species: human    Sample: non-tumour and tumour

FIGURE 1|M2 macrophage infiltration and IL-33 production are enhanced with close correlation in oesophageal squamous cell carcinoma (ESCC). A, Representative images of IL-33+ cell, CD206+ cell and CD68+ cell in non-tumour and tumour tissue (scale bar = 50 μm).B, Western blot analysis of IL-33 and CD206 expression in non-tumour and tumour tissues, and GAPDH was used as a reference control.
3). SUMOylated IL-33 in the nucleus stabilizes the transcription factor IRF1 in hepatocellular carcinoma cells to promote immune escape. Science Signaling (PubMed: 36917642) [IF=7.3]
4). Quercetin Ameliorates Renal Injury and Pyroptosis in Lupus Nephritis through Inhibiting IL-33/ST2 Pathway In Vitro and In Vivo. Antioxidants (PubMed: 36421424) [IF=7.0]
5). Decreased intracellular IL-33 impairs endometrial receptivity in women with adenomyosis. Frontiers in Endocrinology (PubMed: 35937844) [IF=5.2]

Application: WB    Species: Human    Sample: endometria

Figure 1 IL33 is aberrantly expressed in the endometria of women with adenomyosis. (A) IL33 and HOXA10 protein expression in normal (n = 20) and patients with adenomyosis (n = 20) was analyzed by Western blot. (B) The intensities of IL33 signals were quantified from the 20 samples and normalized. to GAPDH. ***p < 0.001. (C) The intensities of HOXA10 signals were quantified from the 20 samples and. normalized to GAPDH. **p < 0.01. (D) Correlation between IL33 and HOXA10 protein expression levels (r = 0.7788, p < 0.0001). (E) Timed mid-secretory endometrial biopsies from healthy control and infertile women with adenomyosis were analyzed using immunohistochemistry (IHC). Rabbit or Goat IgG was used as the negative control. The arrows show the decreased IL33 and HOXA10 conjugates in the endometrial epithelium cell. (F) The integrated optical densities (IOD) of the expression of IL33 and HOXA10 in the endometrium using Image-Pro Plus System 6.0 image analysis software. (G) The mean density of the expression of IL33 and HOXA10 in the endometrium. using Image-Pro Plus System 6.0 image analysis software.

Application: IHC    Species: Human    Sample: endometria

Figure 1 IL33 is aberrantly expressed in the endometria of women with adenomyosis. (A) IL33 and HOXA10 protein expression in normal (n = 20) and patients with adenomyosis (n = 20) was analyzed by Western blot. (B) The intensities of IL33 signals were quantified from the 20 samples and normalized. to GAPDH. ***p < 0.001. (C) The intensities of HOXA10 signals were quantified from the 20 samples and. normalized to GAPDH. **p < 0.01. (D) Correlation between IL33 and HOXA10 protein expression levels (r = 0.7788, p < 0.0001). (E) Timed mid-secretory endometrial biopsies from healthy control and infertile women with adenomyosis were analyzed using immunohistochemistry (IHC). Rabbit or Goat IgG was used as the negative control. The arrows show the decreased IL33 and HOXA10 conjugates in the endometrial epithelium cell. (F) The integrated optical densities (IOD) of the expression of IL33 and HOXA10 in the endometrium using Image-Pro Plus System 6.0 image analysis software. (G) The mean density of the expression of IL33 and HOXA10 in the endometrium. using Image-Pro Plus System 6.0 image analysis software.
6). Electroacupuncture prevents the development or establishment of chronic pain via IL-33/ST2 signaling in hyperalgesic priming model rats. Neuroscience letters (PubMed: 38142925) [IF=2.5]

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.